<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Enroll Your Immuno-Oncology Agents in Our Next MuScreen™ Today

MuScreen is the first high throughput in vivo screen for evaluating immunotherapy and immune modulating compounds across both well-characterized syngeneic and unique tumor homograft models.

Agent efficacy is evaluated using syngeneic and/or tumor homograft model panels, with PD effects assessed using syngeneic models only. MuScreen is a cost-effective screening platform, with a free vehicle arm and shared cost of the positive control arm.

Select the Models and Study Design to Suit Your Program

Model Type Model  Features
Efficacy PD
US
China
US
China
Syngeneic Display immune heterogeneity
and diversity observed
in the clinic
6
models
6
models
12
models
Tumor Homograft   Transplants of GEMM tumors
into a syngeneic host, preserving
original GEMM tumor molecular
and histopathology and clinically
relevant oncogenic driver mutations
  6
models
   


MuScreen Schedules

Syngeneic

12 Model Efficacy and PD Mode
Study Site: Crown Bioscience China
Registration Deadline
Study Initiation
January 28th, 2022
February 25th, 2022
April 15th, 2022
May 13th, 2022
July 15th, 2022
August 12th, 2022
September 16th, 2022
October 14th, 2022
 
6 Model Syngeneic Efficacy and PD Mode
Study Site: Crown Bioscience San Diego
Registration Deadline
Study Initiation
January 14th, 2022
February 14th, 2022
March 18th, 2022
April 18th, 2022
May 20th, 2022
June 20th, 2022
August 12th, 2022
September 12th, 2022

Tumor Homograft

6 Model Efficacy Mode
Study Site: Crown Bioscience China
Registration Deadline
Study Initiation
January 14th, 2022
February 25th, 2022
May 6th, 2022
June 17th, 2022
September 2nd, 2022
October 14th, 2022



Register Your Interest!

Your privacy is important to us.
We'll never share your information.